» Articles » PMID: 35671390

The Genetic Landscape of Germline DDX41 Variants Predisposing to Myeloid Neoplasms

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2022 Jun 7
PMID 35671390
Authors
Affiliations
Soon will be listed here.
Abstract

Germline DDX41 variants are the most common mutations predisposing to acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) in adults, but the causal variant (CV) landscape and clinical spectrum of hematologic malignancies (HMs) remain unexplored. Here, we analyzed the genomic profiles of 176 patients with HM carrying 82 distinct presumably germline DDX41 variants among a group of 9821 unrelated patients. Using our proposed DDX41-specific variant classification, we identified features distinguishing 116 patients with HM with CV from 60 patients with HM with variant of uncertain significance (VUS): an older age (median 69 years), male predominance (74% in CV vs 60% in VUS, P = .03), frequent concurrent somatic DDX41 variants (79% in CV vs 5% in VUS, P < .0001), a lower somatic mutation burden (1.4 ± 0.1 in CV vs 2.9 ± 0.04 in VUS, P = .012), near exclusion of canonical recurrent genetic abnormalities including mutations in NPM1, CEBPA, and FLT3 in AML, and favorable overall survival (OS) in patients with AML/MDS. This superior OS was determined independent of blast count, abnormal karyotypes, and concurrent variants, including TP53 in patients with AML/MDS, regardless of patient's sex, age, or specific germline CV, suggesting that germline DDX41 variants define a distinct clinical entity. Furthermore, unrelated patients with myeloproliferative neoplasm and B-cell lymphoma were linked by DDX41 CV, thus expanding the known disease spectrum. This study outlines the CV landscape, expands the phenotypic spectrum in unrelated DDX41-mutated patients, and underscores the urgent need for gene-specific diagnostic and clinical management guidelines.

Citing Articles

Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding.

Kida J, Chlon T Curr Opin Hematol. 2024; 32(2):67-76.

PMID: 39564659 PMC: 11781971. DOI: 10.1097/MOH.0000000000000854.


Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts.

Hendricks R, Kim J, Haley J, Ramos M, Mirshahi U, Carey D Leukemia. 2024; 39(2):400-411.

PMID: 39501104 PMC: 11794151. DOI: 10.1038/s41375-024-02436-y.


Genome sequencing in the management of myelodysplastic syndromes and related disorders.

Cazzola M, Malcovati L Haematologica. 2024; 110(2):312-329.

PMID: 39445412 PMC: 11788631. DOI: 10.3324/haematol.2023.284947.


How we diagnose Myelodysplastic syndromes.

Oster H, Mittelman M Front Oncol. 2024; 14:1415101.

PMID: 39346739 PMC: 11427428. DOI: 10.3389/fonc.2024.1415101.


Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea.

Kwon J, Kim H, Lee J, Hong Y, Kang H, Jang Y Cancers (Basel). 2024; 16(13).

PMID: 39001408 PMC: 11240339. DOI: 10.3390/cancers16132346.


References
1.
Chlon T, Stepanchick E, Hershberger C, Daniels N, Hueneman K, Davis A . Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021; 28(11):1966-1981.e6. PMC: 8571055. DOI: 10.1016/j.stem.2021.08.004. View

2.
Kerber R, OBrien E . A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer. 2005; 103(9):1906-15. DOI: 10.1002/cncr.20989. View

3.
Pinto E Vairo F, Ferrer A, Cathcart-Rake E, King R, Howard M, Viswanatha D . Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia. Leuk Lymphoma. 2018; 60(5):1337-1339. PMC: 6472976. DOI: 10.1080/10428194.2018.1522443. View

4.
Polprasert C, Takeda J, Niparuck P, Rattanathammethee T, Pirunsarn A, Suksusut A . Novel DDX41 variants in Thai patients with myeloid neoplasms. Int J Hematol. 2019; 111(2):241-246. DOI: 10.1007/s12185-019-02770-3. View

5.
Huang K, Mashl R, Wu Y, Ritter D, Wang J, Oh C . Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018; 173(2):355-370.e14. PMC: 5949147. DOI: 10.1016/j.cell.2018.03.039. View